Yousif Capital Management LLC Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Yousif Capital Management LLC lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.0% in the 1st quarter, HoldingsChannel reports. The fund owned 16,207 shares of the biotechnology company’s stock after selling 160 shares during the period. Yousif Capital Management LLC’s holdings in United Therapeutics were worth $4,996,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter worth about $25,000. Dunhill Financial LLC boosted its holdings in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after buying an additional 50 shares during the period. State of Wyoming purchased a new position in United Therapeutics in the 4th quarter valued at approximately $62,000. Curat Global LLC purchased a new position in United Therapeutics in the 1st quarter valued at approximately $63,000. Finally, Millstone Evans Group LLC bought a new stake in United Therapeutics during the 4th quarter valued at $67,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $276.47 on Thursday. The firm has a market cap of $12.47 billion, a P/E ratio of 12.14, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $266.98 and a 1 year high of $417.82. The stock has a 50 day simple moving average of $300.54 and a two-hundred day simple moving average of $332.08.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm earned $6.17 EPS. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on UTHR. Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Morgan Stanley increased their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a report on Thursday, May 1st. Finally, Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $393.08.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This represents a 23.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,500 shares of company stock worth $20,828,390 over the last three months. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.